Cover Image
市場調查報告書

全球液態切片引進趨勢的調查:2015年

2015 Global Survey on Liquid Biopsy Adoption Trends

出版商 Frost & Sullivan 商品編碼 344678
出版日期 內容資訊 英文 86 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球液態切片引進趨勢的調查:2015年 2015 Global Survey on Liquid Biopsy Adoption Trends
出版日期: 2015年11月04日 內容資訊: 英文 86 Pages
簡介

本報告提供液態切片 (液體細胞診斷) 的利用相關現在/未來的引進模式調查分析、現在/未來的利用、引進的時限、主要的細胞的種類、樣品種類的偏好、相關分析、將來有力的應用、主要方法、檢測技術、供應商的普及度、引進的障礙等相關的系統性資訊。

調查背景、目的、手法、受訪者的人口統計

摘要整理

液態切片的利用全體

  • 液態切片的利用全體:組織的各類型
  • 未來引進的時限
  • 未來引進的時限:組織的各類型
  • 對輔助組織切片檢查使用液態切片的見解

液態切片中偏好的細胞種類與樣品的種類

  • 生物標記的利用全體
  • 生物標記的利用全體:醫院的研究所
  • 生物標記的利用全體:製藥、診斷企業
  • 生物標記的利用全體:標準研究所
  • 生物標記的利用全體:研究機關、大學

工作負載評估

  • 每1個月的樣品數量
  • 樣品形式:全體
  • 樣品形式:目前用戶 vs. 未來的用戶
  • 樣品形式:組織的各類型

主要利用的技術

  • ctDNA檢測:概要
  • ctDNA檢測:現在/未來的用戶趨勢
  • ctDNA檢測:組織的各類型
  • CTC檢測:概要
  • CTC檢測:現在/未來的用戶趨勢
  • CTC檢測:組織的各類型

液態切片:有力的應用和障礙

  • 精通腫瘤分析的品牌
  • 液態切片中的有力的應用 (全體)
  • 有力的應用:組織的各類型
  • 有力的應用:現在/未來的用戶
  • 液態切片的障礙
  • 障礙:生物標記的各類型

腫瘤分析的方法,檢測技術

  • 對簡介類型的液態切片的利用
  • 腫瘤分析:組織的各類型
  • 液態切片的方法:現在/未來的用戶
  • 液態切片的方法:組織的各類型
  • 樣品種類與液態切片的方法的相關
  • CTC固有的液態切片的方法:現在/未來的用戶
  • ctDNA固有的液態切片的方法:現在/未來的用戶
  • 生殖細胞系列/cfDNA固有的液態切片的方法:現在/未來的用戶
  • EV固有的液態切片的方法:現在/未來的用戶

品牌認識

  • 整體品牌認識
  • 品牌認識:組織的各類型
  • 現在/未來品牌認識前7大
  • 品牌偏好:生物標記的各類型 (CTC)
  • 品牌偏好:生物標記的各類型 (ctDNA)
  • 品牌偏好:生物標記的各類型 (生殖細胞系列、cfDNA)
  • 品牌偏好:生物標記的各類型 (EV)

償付方案

  • 償付趨勢 (全體)
  • 償付趨勢:組織的各類型
  • 償付趨勢:各技術 (ctDNA)
  • 償付趨勢:各技術 (CTC)

變異對立遺傳基因的限制 (逐字逐句回答)

  • 變異對立遺傳基因的檢測限制:診斷和監測

喜歡血液作為樣品種類的理由 (逐字逐句回答)

  • 比起其他樣品種類更喜歡血液的理由
  • 免責聲明

附錄

關於Frost&Sullivan

目錄
Product Code: 9AB9-00-2F-00-00

Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA-A Voice of Customer Study

The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:

  • Current and future use of liquid biopsy by organization type
  • Timeframe of liquid biopsy adoption amidst future users
  • Predominantly used cell types-CTCs, ctDNA, cfDNA and Evs-by organization type
  • Sample inflow to conduct liquid biopsy tests
  • Preference for sample types: blood, saliva, stool, serum, and so on.
  • Correlation analysis of sample type and biomarker type
  • Promising applications for liquid biopsy-current and future
  • Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
  • Technologies used to detect CtDNA-current vs. future users
  • Technologies used to detect CTCs
  • Vendor popularity for specific biomarkers and reimbursement scenario
  • Bottlenecks to mainstream implementation of liquid biopsy

Table of Contents

1. 2015 GLOBAL SURVEY ON LIQUID BIOPSY ADOPTION TRENDS

Research Background, Objectives, Methodology, and Respondent Demographics

  • 1. Research Objectives
  • 2. Research Methodology
  • 3. Research Methodology (continued)
  • 4. Respondent Demographics
  • 5. Respondent Demographics (continued)
  • 6. Respondent Demographics-Current and Future Users

Executive Summary

  • 1. Key Findings
  • 2. Top 7 Brands for Liquid Biopsy

Overall Usage of Liquid Biopsy

  • 1. Overall Use of Liquid Biopsy by Organization Type
  • 2. Timeframe for Future Adoption
  • 3. Timeframe for Adoption by Organization Type
  • 4. Opinion on Use of Liquid Biopsy as an Adjunct to Tissue Biopsy
  • 5. Liquid Biopsy as an Adjunct to Tissue Biopsy (continued)

Preferred Cell Types and Sample Types for Liquid Biopsy

  • 1. Overall Biomarker Usage
  • 2. Overall Biomarker Usage-Hospital Laboratories
  • 3. Overall Biomarker Usage-Pharmaceutical and Diagnostic Companies
  • 4. Overall Biomarker Usage-Reference Laboratories*
  • 5. Overall Biomarker Usage-Research Institutes and Universities

Workload Assessment

  • 1. Sample Volume Per Month
  • 2. Sample Format-Overall
  • 3. Sample Format-Current Users vs. Future Users
  • 4. Sample Format by Organization Type

Predominantly Used Technologies

  • 1. Technologies Used to Detect ctDNA-Overview
  • 2. Technologies Used to Detect ctDNA-Current and Future User Trends
  • 3. Technologies Used to Detect ctDNA by Organization Type
  • 4. Technologies Used to Detect CTC-Overview
  • 5. Technologies Used to Detect CTC-Current and Future User Trends
  • 6. Technologies Used to Detect CTC by Organization Type

Liquid Biopsy-Promising Applications and Bottlenecks

  • 1. Brand Familiarity for Tumor Profiling
  • 2. Promising Applications of Liquid Biopsy (Overall)
  • 3. Promising Applications by Organization Type
  • 4. Promising Applications-Current and Future Users
  • 5. Bottlenecks in Liquid Biopsy
  • 6. Bottlenecks by Biomarker Type

Tumor Profiling Approaches, Technologies for Detection

  • 1. Liquid Biopsy Usage to Profile Types
  • 2. Tumor Profiling by Organization Type
  • 3. Liquid Biopsy Approaches-Current vs. Future Users
  • 4. Liquid Biopsy Approach by Organization Type
  • 5. Correlation of Sample Type and Liquid Biopsy Approach
  • 6. CTC-Specific Liquid Biopsy Approaches-Current vs. Future Users
  • 7. ctDNA-Specific Liquid Biopsy Approaches-Current vs. Future Users
  • 8. Germline or cfDNA-Specific Liquid Biopsy Approaches-Current vs. Future Users
  • 9. EVs-Specific Liquid Biopsy Approaches-Current vs. Future Users

Brand Perception

  • 1. Overall Brand Perception
  • 2. Brand Perception Organization Type
  • 3. Top 7 Current and Future Brand Perception
  • 4. Brand Preference by Biomarker Type-CTCs
  • 5. Brand Preference by Biomarker Type-CtDNA
  • 6. Brand Preference by Biomarker Type-Germline and cfDNA
  • 7. Brand Preference by Biomarker Type-Evs

Reimbursement Scenario

  • 1. Reimbursement Trends (Overall)
  • 2. Reimbursement Trend by Organization Type
  • 3. Reimbursement by Technology-ctDNA
  • 4. Reimbursement by Technology-CTC

Mutant Allele Limit (Verbatim Reponses)

  • 1. Mutant Allele Detection Limit-Diagnosis and Monitoring

Reasons for Preferring Blood as a Sample Type(Verbatim Reponses)

  • 1. Reasons for Choosing Blood Over Other Sample Types
  • 2. Reasons for Choosing Blood Over Other Sample Types (continued)
  • 3. Reasons for Choosing Blood Over Other Sample Types (continued)
  • 4. Reasons for Choosing Blood Over Other Sample Types (continued)
  • 5. Reasons for Choosing Blood Over Other Sample Types (continued)
  • 6. Legal Disclaimer

Appendix

  • 1. Additional Sources of Information

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition-Future of Your Company & Career
  • 3. North America and Europe Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top